Suomi - suomi - Fimea (Suomen lääkevirasto)

chanelle pharmaceuticals manufacturing limited - miconazole nitrate, polymyxin b sulfate, prednisolone acetate - korvatipat, suspensio - 23.0 mg/ml + 5.0 mg/ml + 5500 iu/ml - prednisoloni ja mikrobilääkkeet

Suomi - suomi - Fimea (Suomen lääkevirasto)

s.a. alcon couvreur n.v. - sulfacetamidum natricum,prednisoloni acetas - silmätipat - prednisoloni ja mikrobilääkkeet

Suomi - suomi - Fimea (Suomen lääkevirasto)

schering oy - cinchocaini hydrochloridum,clemizoli undecylenas,prednisoloni caproas - rektaalivoide - prednisoloni

Suomi - suomi - Fimea (Suomen lääkevirasto)

schering oy - cinchocaini hydrochloridum,clemizoli undecylenas,prednisoloni caproas - peräpuikko - prednisoloni

Suomi - suomi - Fimea (Suomen lääkevirasto)

novartis pharma stein ag - clioquinolum,prednisoloni pivalas - liuos iholle ja korviin - prednisoloni ja mikrobilääkkeet

Suomi - suomi - Fimea (Suomen lääkevirasto)

novartis consumer health sa - hexachlorophenum,troxerutinum,prednisoloni pivalas - peräpuikko - prednisoloni

Suomi - suomi - Fimea (Suomen lääkevirasto)

allergan inc. - phenylephrini hydrochloridum,prednisoloni acetas,sulfacetamidum natricum - silmätipat - prednisoloni

Euroopan unioni - suomi - EMA (European Medicines Agency)

accord healthcare s.l.u. - abirateroniasetaatti - prostatiset kasvaimet - endokriinihoito - abiraterone accord is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt)the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicatedthe treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.

Euroopan unioni - suomi - EMA (European Medicines Agency)

mylan ireland limited - abirateroniasetaatti - prostatiset kasvaimet - endocrine therapy, other hormone antagonists and related agents - abiraterone mylan is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt). the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated. the treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.

Euroopan unioni - suomi - EMA (European Medicines Agency)

krka, d.d., novo mesto - abirateroniasetaatti - prostatiset kasvaimet - endokriinihoito - abiraterone krka is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt) (see section 5. 1)the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. 1)the treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen.